
Pietro Mazzeo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4637744/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry. IJC Heart and Vasculature, 2020, 27, 100486.	0.6	33
2	Difficult-to-control hypertension: identification of clinical predictors and use of ICT-based integrated care to facilitate blood pressure control. Journal of Human Hypertension, 2018, 32, 467-476.	1.0	22
3	The Italian version of the quick mild cognitive impairment (Qmci-l) screen: normative study on 307 healthy subjects. Aging Clinical and Experimental Research, 2019, 31, 353-360.	1.4	20
4	Vitamin D, parathyroid hormone and cardiovascular risk. Journal of Cardiovascular Medicine, 2018, 19, 62-66.	0.6	18
5	Serum Uric Acid and Left Ventricular Mass in Essential Hypertension. Frontiers in Cardiovascular Medicine, 2020, 7, 570000.	1.1	14
6	Liver disease and heart failure. Panminerva Medica, 2020, 62, 26-37.	0.2	14
7	Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2022, 36, 1157-1164.	1.3	13
8	Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenterÂltalian register. European Heart Journal Open, 2022, 2, .	0.9	11
9	New Targets in Heart Failure Drug Therapy. Frontiers in Cardiovascular Medicine, 2021, 8, 665797.	1.1	10
10	Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF. ESC Heart Failure, 2022, 9, 2909-2917.	1.4	10
11	Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan. Acta Cardiologica, 2021, , 1-6.	0.3	7
12	Predictors of right ventricular function improvement with sacubitril/valsartan in a realâ€life population of patients with chronic heart failure. Clinical Physiology and Functional Imaging, 2021, 41, 505-513.	0.5	7
13	Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation. Thrombosis Research, 2020, 195, 16-20.	0.8	5
14	The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic. Cardiovascular Drugs and Therapy, 2023, 37, 341-351.	1.3	3
15	Multivessel spontaneous coronary artery dissection and Crohn's disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, e26-e28.	0.6	1
16	25 Atrial remodelling in patients affected by chronic heart failure in therapy with sacubitril/valsartan. European Heart Journal Supplements, 2021, 23, .	0.0	0
17	63 Peripheral endothelial function in patients affected by pulmonary hypertension. Relationship between endothelial function, haemodynamic parameters, and therapy response. European Heart Journal Supplements, 2021, 23, .	0.0	0
18	37 Prognostic role of the lung ultrasound in the acute coronary syndrome. European Heart Journal Supplements, 2021, 23, .	0.0	0

#	Article	IF	CITATIONS
19	62 Biventricular evaluation of gliflozines effects in chronic heart failure patients function (begin-HF) Tj ETQq1 I	1 8.78431	4 rgBT /Over
20	266 Deformation imaging by strain in chronic heart failure over sacubitril–valsartan: a multicentre echocardiographic registry (discover)—ARNI. European Heart Journal Supplements, 2021, 23, .	0.0	0
21	24 Gliflozins and ventricular function in patients affected by chronic heart failure with diabetes mellitus. European Heart Journal Supplements, 2021, 23, .	0.0	0
22	61 Right ventricular function in patient with heart failure with reduced ejection fraction and sacubitril/valsartan treatment. European Heart Journal Supplements, 2021, 23, .	0.0	0